Dernières nouvelles pour Global X Clean Water ETF (NASDAQ:AQWA)

Industrials

Utilities

Basic Materials

Consumer Cyclical

Real Estate

Other

The Fund invests at least 80 percent of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive Global Clean Water Industry Index (the Underlying Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed.

Ecolab, Inc.

Xylem Inc./ NY

American Water Works Co. Inc.

Severn Trent Plc

Pentair Plc

Core & Main Inc

Essential Utilities Inc - Common

Ao Smith Corp.

Advanced Drainage Systems Inc

United Utilities

Ferguson Enterprises Inc. Of Delaware

Companhia De Saneamento Basico Do Estado De Sao Paulo Sabesp

Global X Clean Water ETF

Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release third-quarter earnings results before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Thursday, April 24.</a>
Analysts expect the Cincinnati, Ohio-based company to report quarterly earnings at $1.53 per share, up from $1.52 per share in the year-ago period. Procter &amp; Gamble projects to report quarterly revenue at $20.15 billion, compared to $20.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, RBC Capital analyst Nik Modi reiterated Procter &amp; Gamble with a Sector Perform rating and maintained a $164 price target.
With the recent buzz around Procter &amp; Gamble, some investors may be eyeing potential gains from the company's dividends too. Currently, Procter &amp; Gamble offers an annual dividend yield of 2.52%. That&#8217;s a quarterly dividend amount of $1.06 per share ($4.227 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $238,222 or around 1,419 shares. For a more modest $100 per month or $1,200 per year, you would need $47,678 or around 284 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.227 in this case). So, $6,000 / $4.227 = 1,419 ($500 per month), and $1,200 / $4.227 = 284 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
PG Price Action: Shares of Procter &amp; Gamble gained 1.3% to close at $167.88 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

News

Markets

Trading Ideas

How To Earn $500 A Month From Procter & Gamble Stock Ahead Of Q3 Earnings

The world's largest <a target="_blank" href="https://www.benzinga.com/topic/mining" rel="noreferrer noopener">miner</a>, BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), is reportedly preparing for a leadership transition as CEO Mike Henry's tenure approaches its expected conclusion.
While no formal announcement has been made, company insiders suggested the board could initiate the succession process soon, with a potential handover in early 2026.
According to information the company's insiders shared <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-23/bhp-prepares-to-start-succession-process-for-mining-s-top-job" rel="noreferrer noopener">with</a> Bloomberg, three candidates are at the forefront of the succession process.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44709462" rel="noreferrer noopener">Miners Urge Chile To Cut Bureaucracy Before Country Loses Copper Leadership</a>
Geraldine Slattery, who currently oversees BHP's Australian operations, brings extensive experience, having previously managed the company's oil and gas division before its merger with Woodside.
Chief Financial Officer Vandita Pant, a former banker who joined BHP in 2016, has risen rapidly with her financial expertise. Then, there is Ragnar Udd, the commercial chief who has driven the success of BHP's copper business in the Americas.
Selecting either Slattery or Pant would mean that BHP would have its first female CEO in its 140-year history.
Henry assumed the top job in January 2020, taking over from Andrew Mackenzie, who had streamlined BHP's portfolio during a seven-year tenure. Thus, Henry's potential six-year term would align with his predecessor's.
As a company veteran of three decades, Henry previously led BHP's Australian minerals division and held key roles in operations, marketing, and technology.
Under his leadership, significant milestones have occurred, including the exit from petroleum through the Woodside merger, the simplification of BHP's dual-listed structure, and the approval of the massive Jansen potash project in Canada.
However, his boldest move, <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">a $49 billion bid</a> for Anglo American, ultimately collapsed when the target rejected the offer as too complex. This dealt a blow to BHP's copper growth ambition, prompting upper management to seek a solution in a <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">joint venture with </a><a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">Lundin</a>.
Henry's successor will inherit both opportunities and challenges. The firm is committing billions to expand in future-facing commodities like copper and potash while maintaining iron ore as its core business.
Still, mining capex is notoriously high, and with nearly $20 billion of debt on the balance sheet, the company is already near the upper limit of its debt targets.
The iron ore business, which delivered 290 million tons in 2024, faces particular headwinds. Analysts at Goldman Sachs forecast prices could slump to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44651093/iron-ore-set-to-slide-further-as-trump-tariffs-china-slowdown-collide-goldman-says" rel="noreferrer noopener">$84 per ton</a> by late 2025 amid oversupply concerns and softening Chinese demand, while BMI anticipates the oversupply could continue till the end of the decade.
Price Action: BHP stock is up 3.06% to $49.11 premarket at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44932257/billionaire-john-paulson-buys-800-million-stake-in-alaskan-gold-mine-as-gold-hits-record-highs" target="_blank" rel="noreferrer noopener">Billionaire John Paulson Buys $800 Million Stake In Alaskan Gold Mine As Gold Hits Record Highs</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Large Cap

Rumors

Commodities

Management

Media

World's Largest Miner BHP Quietly Prepares For CEO Succession

Baird analyst Jeffrey Meuler maintains Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Outperform and lowers the price target from $575 to $525.

Price Target

Analyst Ratings

Baird Maintains Outperform on Moodys, Lowers Price Target to $525

WIIM

BMRA

Biomerica shares are trading higher after the United Arab Emirates Ministry of Health and Prevention approved for sale its Fortel Ulcer Test for the detection of H. pylori infection.

Baird analyst Rob Oliver maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Outperform and lowers the price target from $54 to $37.

KVYO

Baird Maintains Outperform on Klaviyo, Lowers Price Target to $37

TSLA

Tesla shares are trading higher after the company reported Q1 results and CEO Elon Musk indicated his time allocation to DOGE would drop. Additionally, Wedbush raised its price target from $315 to $350.

<ul>
<li>10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer</li>
<li>Approximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogen</li>
<li>This test empowers healthcare providers with fast, accessible testing across the UAE &nbsp;</li>
</ul>
IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>), a global provider of advanced diagnostic solutions, announced today that its Fortel&#xAE; Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE—a region where gastrointestinal diseases are a growing public health concern.
The Fortel&#xAE; Ulcer Test is a simple, quick and user-friendly diagnostic tool that detects antibodies to H. pylori, a bacterium known to cause peptic ulcer disease, dyspepsia, and gastric cancer. The test delivers accurate results in just 10 minutes.

Biotech

Global

General

Biomerica's Fortel Ulcer Test Approved For Sale In UAE, Enabling Rapid 10-Minute Detection Of Helicobacter pylori, A Class 1 Carcinogen Linked To 80% Of Gastric Cancer Cases—Offering Fast, Accessible Diagnostic Tool Amid Growing Regional GI Health Concerns

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $4 price target.

Chardan Capital Maintains Buy on Unity Biotechnology, Maintains $4 Price Target

NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">earlier than previously guided</a>.&nbsp;
NeuroOne Medical is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation.
In March, the company accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025. The company had previously projected a submission by the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44245575/neuroone-accelerates-timeline-of-510-k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-s" rel="noreferrer noopener">end of June 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
The submission leverages the company's proprietary OneRF Ablation System RF generator platform for trigeminal neuralgia, a chronic pain condition affecting approximately 100,000 people in the U.S.
The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition.
Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression, radiosurgery, or other percutaneous techniques.
The OneRF trigeminal nerve ablation technology features a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue and relieve severe, chronic pain in the face.
According to the October 2024 report, the trigeminal neuralgia therapeutics market, comprised of pharmacologic and surgical technologies, is expected to grow from $262 million in 2024 to over $416 million by 2030, primarily due to an aging population.
The multi-contact probe is designed for multi-point mapping of pain location, stimulation, and ablation, all using the same electrode and with the safety of temperature-controlled ablation.
These features are also present in the FDA 510(k) cleared OneRF sEEG (brain) Ablation System.
Previously published data have shown that RF ablation offers high initial pain relief rates (~95%) and long-term efficacy, especially with repeat treatments, while maintaining a low complication rate.
Dave Rosa, President and CEO of NeuroOne, stated: "Our OneRF ablation technology platform has already achieved successful commercialization and patient outcomes in lesioning nerve tissue for functional neurosurgical procedures, such as the treatment of epilepsy. Expanding into facial pain broadens the clinical impact of our technology and further validates the versatility and scalability of our platform."
"If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025."
Earlier in April, &nbsp;NeuroOne Medical priced an underwritten registered public offering of 16 million shares at 50 cents per share, around <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44645150/neuroone-medical-technologies-corporation-announces-pricing-of-8-0-million-public-offering-of-comm" rel="noreferrer noopener">$8 million in gross proceeds</a>.
Price Action: NMTC stock closed at $0.54 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44938778/danaher-pricing-strategy-key-to-navigating-tariff-challenges-analyst" target="_blank" rel="noreferrer noopener">Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

NMTC

EXCLUSIVE: NeuroOne Submits FDA Marketing Application For OneRF Trigeminal Nerve Ablation System For Facial Pain

EXCLUSIVE: NeuroOne Tells Benzinga Co. Completes FDA Submission For The OneRF Trigeminal Nerve Ablation System To Treat Facial Pain, Says 'Submission Completed Earlier Than Anticipated'

Baird analyst Ben Kallo maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $370 to $320.

Baird Maintains Outperform on Tesla, Lowers Price Target to $320

Ahead of Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) first-quarter earnings, this analyst expects Google's parent to deliver on the advertising revenue and expects an "earnings surprise."
What Happened: The Chairman and Founder of Navellier &amp; Associates, Louis Navellier, spoke about Alphabet's first quarter forecast in his podcast ‘Market Buzz'.
&#8220;Well, their sales are forecasted to go up 10.7%, and earnings are forecast to grow 7%. Google does not provide any guidance whatsoever, but it has a very good earnings surprise history. I think what everybody&#8217;s going to be looking at is their advertising revenue very carefully," he said.
According to him, March's strong retail sales will help push Google's<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44909414/google-parent-alphabets-topline-can-withstand-pressure-in-uncertain-macro-scenario-compared-to-peers-analyst"> advertising revenue</a> in the said quarter. &#8220;Based on the strong retail sales we had in March, the strongest in two years, I would think Google&#8217;s advertising revenue would pick up.&#8221;
Last week, a <a href="https://www.benzinga.com/news/legal/25/04/44876356/google-scores-partial-win-in-antitrust-case-but-faces-setback-on-publisher-tools">U.S. District Judge ruled</a> that the Department of Justice won its antitrust case against Alphabet&#8217;s Google, finding the company illegally monopolized advertising technology. 
The ruling concluded that Google engaged in anticompetitive practices for over a decade by bundling its publisher ad server and ad exchange to maintain its monopoly in those open-web display ad markets.
Navellier added, &#8220;The only glitch is, of course, the Department of Justice has won a suit against them to break them up. You know, breaking up Google is kind of like a dog catching a car. I mean, what does the dog do now? They&#8217;re trying to appease the government, and I&#8217;m sure with Trump in it&#8217;s going to be a little different, but I think they&#8217;re trying to spin off Chrome, so we&#8217;ll see what happens, but Google normally beats.&#8221;
See Also: <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">Wedbush&#8217;s Dan Ives Raises Tesla&#8217;s Price Target To $350 As Elon Musk Promises To &#8216;Significantly&#8217; Reduce DOGE Time</a>
Why It Matters: The company will be reporting its first-quarter earnings on April 24. Alphabet's technical charts indicated that its premarket price of $157.66 per share at the time of the publication was above its short-term simple daily moving averages but below its long-term averages.
The relative strength index of 43.78 was neutral, whereas its MACD line was at negative 4.04. However, its 12-day exponential moving average was above the 26-day EMA, with a positive histogram of 0.47, indicating a bullish trend.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png" alt="" class="wp-image-883854" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The stock was up 2.44% in premarket, but it has fallen by 19.27% on a year-to-date basis. It was 3.76% lower over the year.
Benzinga Edge Stock Rankings shows that GOOG had a weaker price trend over the short, medium, and long term. Its momentum ranking was moderate at the 48.43 percentile, whereas its value ranking was also moderate; the details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>. 
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/report/TSLA"><img loading="lazy" decoding="async" width="1024" height="146" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png" alt="" class="wp-image-883853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 2.50% to $540.42, while the QQQ advanced 3.20% to $457.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44945107/bearish-charts-and-upbeat-q1-estimates-heres-how-chipotle-stock-is-doing-after-recent-pric">Chipotle Stock Faces Bearish Charts Despite Upbeat Q1 Estimates And Price Target Revisions</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Earnings Beats

Earnings Misses

Equities

Market Summary

Broad U.S. Equity ETFs

Guidance

Futures

Technicals

ETFs

GOOG

GOOGL

NFLX

'Google Normally Beats,' Says Analyst Expecting Sundar Pichai-Led Company's Ad Revenue To 'Pick Up' In Q1: Here's What Alphabet's Chart Shows Ahead Of Earnings

William Blair analyst Brian Drab upgrades Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) from Market Perform to Outperform.

Upgrades

William Blair Upgrades Valmont Industries to Outperform

SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics &amp; Orthotics Group LLC ("Bionic P&amp;O"), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego&#xAE; Personal device distributor.

EKSO

Ekso Bionics Holdings Selects Bionic Prosthetics & Orthotics Group As Non-Exclusive Ekso Indego Personal Device Distributor

Baird analyst Michael Halloran maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and lowers the price target from $114 to $107.

Baird Maintains Outperform on Pentair, Lowers Price Target to $107

Newly allowed patent extends Wearable Devices' innovative gesture technology into the domain of voice control
YOKNEAM ILLIT, ISRAEL, April 23, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced that the United States Patent and Trademark Office has allowed its patent titled "Gesture and Voice-Controlled Interface Device."
This patent represents a significant advancement in the Company's strategic intellectual property ("IP") portfolio, strengthening global protection for its core innovations in wearable bio-potential sensors. The Company's IP strategy includes patent families designed to protect a wide spectrum of future applications, ensuring agility in response to emerging global market needs.

WLDS

Wearable Devices Granted U.S. Patent For Gesture And Voice-Controlled Interface Device

ONMD

OneMedNet And Protege Partner To Enable Real-Time Access, Multimodal Patient Data For AI Developers And Researchers

Baird analyst Mircea Dobre maintains Herc Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) with a Neutral and lowers the price target from $129 to $110.

Baird Maintains Neutral on Herc Holdings, Lowers Price Target to $110

UBS analyst Peter Grom initiates coverage on Simply Good Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) with a Neutral rating and announces Price Target of $41.

Initiation

SMPL

UBS Initiates Coverage On Simply Good Foods with Neutral Rating, Announces Price Target of $41

Norfolk Southern Affirms FY2025 Sales Guidance of $12.49B vs $12.37B Est

Comments

Global X Clean Water ETF

Actualités

Dernières nouvelles pour Global X Clean Water ETF (NASDAQ:AQWA)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL